On air · 1 of 3 networks
Gerresheimer
- gerresheimer.com
- Healthcare & Life Sciences
- DE
- 3,817 employees
Gerresheimer’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 38. Watch Gerresheimer with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 16 | Checked 28 Oct 2026 | See all 38 ads → | ||
| Meta | Not checked | — | |||
| Recently | 18 | Ads on the Google Ads Transparency Center | Checked 14 Oct 2026 | Collect them with the API → |
Gerresheimer has 16 live LinkedIn ads. We recorded 18 Google ads on 14 Oct 2026.
Latest ads
- LINKEDIN · JOBSince 22 Oct 2026
- LINKEDIN · IMAGESince 15 Apr 2026
In intravitreal injections, consistency is patient safety. Precision in intravitreal injections isn’t just a technical goal—it’s a patient safety imperative. Even minor inconsistencies in microdosing or material performance can introduce risk. In this webinar, we’ll explore how advances in syringe design and development processes are helping reduce variability and support better clinical outcomes. ➡️ Register here: https://lnkd.in/eybhaF4R
- LINKEDIN · IMAGESince 13 Apr 2026
When dosing precision varies, patient risk can rise. Delivering therapies directly to the vitreous demands accuracy at the microliter level—but that precision isn’t always easy to achieve in real‑world practice. In this webinar, we’ll discuss current unmet needs in intravitreal injections, including the risks associated with imprecise dosing and particle formation. Discover how targeted syringe innovations are being developed to better support clinicians and protect patients. 📅 Register today: https://lnkd.in/eybhaF4R
- LINKEDIN · IMAGESince 13 Apr 2026
Intravitreal injections transformed retinal care—what comes next? Intravitreal injections have transformed retinal care—but innovation can’t stand still. From emerging risks to evolving clinician expectations, this webinar looks at where IVIs are today and where they’re headed next. Learn how unmet‑needs analysis, user feedback, and iterative testing are guiding future syringe innovations. 🚀 Learn more: https://lnkd.in/eybhaF4R
- LINKEDIN · IMAGESince 13 Apr 2026
Precision at the microliter level isn’t optional—it’s essential. Intravitreal injections play a critical role in managing retinal diseases like wet AMD and DME, yet achieving consistent, precise microdosing remains a challenge. Small variations in dose volume, particle formation, and handling can impact both procedural efficiency and patient safety. In this webinar, we explore unmet needs in IVIs and share how user‑centric research and iterative development are helping advance safer, more reliable syringe technologies. 🔍 Learn more and register: https://lnkd.in/eybhaF4R
- LINKEDIN · IMAGESince 13 Apr 2026
Millions of injections. One critical question: are today’s tools enough? As the number of intravitreal injections continues to grow worldwide, so does the need for repeatable precision and procedural efficiency. Yet many challenges remain—from dosing variability to handling complexity. Join this webinar to explore how early unmet‑needs identification and iterative development are helping reshape syringe technology for IVIs, with clinician workflows and patient safety front and center. 🔗 Learn more: https://lnkd.in/eybhaF4R
6 of 38 adsSign up to see every Gerresheimer ad, filter by format and date, and get alerts on new ones.
See all 38 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.